Collegium Pharmaceutical (COLL) Stock Rating Lowered by BidaskClub

BidaskClub cut shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a report issued on Tuesday.

A number of other equities research analysts also recently weighed in on COLL. Piper Jaffray Companies set a $23.00 price target on shares of Collegium Pharmaceutical and gave the company a buy rating in a research note on Thursday, December 14th. Needham & Company LLC reiterated a buy rating and issued a $25.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 6th. Jefferies Group reiterated a buy rating and issued a $15.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 6th. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a hold rating to a buy rating and set a $16.00 price objective for the company in a report on Monday, November 13th. Finally, HC Wainwright reiterated a buy rating and issued a $21.00 price objective on shares of Collegium Pharmaceutical in a report on Wednesday, November 8th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Collegium Pharmaceutical presently has a consensus rating of Buy and a consensus price target of $23.33.

Collegium Pharmaceutical (NASDAQ COLL) traded up $0.42 on Tuesday, hitting $18.91. 388,060 shares of the stock were exchanged, compared to its average volume of 340,400. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $20.92. The firm has a market cap of $602.08 and a P/E ratio of -6.37.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.28. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The company had revenue of $11.95 million for the quarter, compared to the consensus estimate of $5.31 million. During the same period last year, the company posted ($1.13) EPS. The firm’s quarterly revenue was up 2814.6% compared to the same quarter last year. analysts expect that Collegium Pharmaceutical will post -2.52 EPS for the current year.

In related news, CEO Michael Thomas Heffernan sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $15.53, for a total value of $776,500.00. Following the completion of the transaction, the chief executive officer now owns 558,987 shares in the company, valued at approximately $8,681,068.11. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Longitude Capital Partners, Ll sold 1,000,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $17.34, for a total transaction of $17,340,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,058,630 shares of company stock valued at $18,264,360. 25.76% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Pura Vida Investments LLC bought a new position in Collegium Pharmaceutical during the 3rd quarter worth approximately $1,229,000. Wells Fargo & Company MN raised its holdings in Collegium Pharmaceutical by 12.8% during the 3rd quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock worth $475,000 after purchasing an additional 5,136 shares during the last quarter. Citadel Advisors LLC raised its holdings in Collegium Pharmaceutical by 773.8% during the 3rd quarter. Citadel Advisors LLC now owns 544,033 shares of the specialty pharmaceutical company’s stock worth $5,707,000 after purchasing an additional 481,771 shares during the last quarter. JPMorgan Chase & Co. bought a new position in Collegium Pharmaceutical during the 3rd quarter worth approximately $192,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Collegium Pharmaceutical during the 3rd quarter worth approximately $201,000. Institutional investors and hedge funds own 79.98% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Collegium Pharmaceutical (COLL) Stock Rating Lowered by BidaskClub” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.com-unik.info/2018/01/10/collegium-pharmaceutical-coll-stock-rating-lowered-by-bidaskclub.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit